HIS & HES Her SCOSE jumps with drugs for Novo Nordisk Loss Loss drugs News ad

From time to time, investors are faced with some of the best names in this industry, which then become the subject of the best news and events during the period of ownership. The best choice today seems to be in the medical sector. He shows investors The main fundamental force This was noticed by other major players in the industry, pushing The future increase in the increaseField

With a large rally of 25% over the past trade week, shares HIS & HES Health Inc. NYSE: Hims became the center of attention for more purchases in the coming months and quarters. A recent price breakthrough is attractive not only for pulse buyers, but also for assessing investors, despite the fact that the shares are already traded with the fact that some can be called “expensive” grades.

Considering that the shares have not raised from accidental price, but rather from a significant announcement that can completely change the future of the company, investors can begin to justify a higher estimate of the price of shares and traditional multiple compared to the rest of the peer group.

Here are some Factors that help markets remain optimistic in its reserveField

Novo Nordisk Collaboration makes a higher ceiling

The leader of the medical industry, Novy Nordisk, announced at the end of April 2025 that he chose His & Hers as his latest partner to spread his flagship drug for weight loss, Wegovy. This solution not only signals about trust in the HIS and HERS business, but is also a strong approval of a wider bull case for the platform.

Earlier, any two were accused of “gaps” found in the company GLP-1 products To control weight and weight loss, referring to the fact that the company did not have enough distribution and size channels to avoid complications in the future.

Now that this new cooperation was landed, the market has gone through most unbelieving shares. This double -digit interest rally has probably removed some of Short sellersSince the maximum painful point is striking, forcing them to close their positions.

As of April 2025, the HIM & Hers shares reported up to 33.3% of their appeals, which are in short positions, which are high in a way. At the same time, the script calling for “Short compressionIn this case, it is viable, including large -scale closure of short positions, which increases the pressure on the purchase in the transition to the shares.

Why His and her still buy

Some may think about the saying on Wall is stroke: If anything gets into Newswire, it is already too late to get into a basic company or trade. In the case of him and her, this is not used today. This belief can be justified by looking at some of the companies Fundamental driversField

According to the last quarterly presentation of income, Hims & Hers today shoots at all cylinders. When it comes to the pillar that contains all together, users, Hims & Gors reported 45% Growth of subscribers Over the past 12 months, showing that the company is still at growth stages.

What User growthreaching up to 2.2 million, allowed HIS & HES to generate up to $ 1.5 billion In income Pure growth 69% Over the past year. Seeing these massive growth topics in the company can begin to justify some bull prospects that can be seen in today’s assessments, especially since new catalysts for future growth are currently appearing.

This is not only growth for him and her. To 90% of the company’s income includes subscriptionsThe creation of capital management and forecasts almost a dream will come true to the creation of VALL -STRATITY values ​​and analysts.

Speaking of analysts, it is here that investors can begin to evaluate where the shares can go further.

The market takes its reserves

Because Khim and her now It is traded by 38% of the 52-week maximum, Investors will notice a relatively low Consensus target price out of 36.9 dollars per share, showing only 5.2% is implied up Where are the shares trading today.

Analysts rarely look at increase or go bulls on promotions which were insufficient or located in the bear territory.

However, when investors study the forecasts of profit per share (EPS), in particular, the forecast for 0.16 US dollars for 3 quarters of 2025, this reflects a significant increase by 77% compared to the current EPS by 0.09 US dollars. Where is the EPS, the price of shares, and this is an analytical opinion that cannot be related to the price action, and to what investors can rely on today.

Perhaps that is why the markets are now ready to pay for 79.7X in price until profit (P/e) ratio, a cool bonus to the rest of the average rating in 22.4x medical sectors. As experienced investors learn, markets always have good reason for overpay for certain sharesAnd Hims & Hers shows quite bull factors to justify the bonus.

Before taking into account his health, you will want to hear it.

Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market will take on the market … and HIS & HES Health was not on the list.

While Hims & Hers Health currently has a retention rating among analysts, analysts with the highest rating believe that these five promotions are better buying.

View five shares here

Like this article? Share this with a colleague.

The link is copied to the exchange buffer.